Mortality risk of bloodstream infection caused by either Escherichia coli or Klebsiella pneumoniae producing extended-spectrum β-lactamase: a prospective cohort study

Table 2 Stratification analysis to evaluate mortality risk among those infected by either E. coli or K. pneumoniae producing ESBL

Strata	RR_Strat	95% CI	p	RR_Crude	RR_MH
Males	1.89	0.59–6.01	0.43	1.38	1.40
Females	0.84	0.2–3.55	1	1.38	1.40
Neonates up to 17 years old	0.78	0.2–2.98	1	1.38	1.64
Adult and elderly	2.57	1.04–6.36	0.04	1.38	1.64
Primary bloodstream infection	1.17	0.33–4.10	0.57	1.38	1.43
Secondary bloodstream infection	1.65	0.61–4.47	0.53	1.38	1.43
Length of stay > 2 days (before bloodstream infection established)	2.13	0.71–6.38	0.29	1.38	1.25
Length of stay ≤ than 2 days (before bloodstream infection established)	0.62	0.21–1.79	0.68	1.38	1.25
Infected by E. coli	0.96	0.29–3.17	0.95	1.38	1.47
Infected by K. pneumoniae	2.05	0.62–6.76	0.37	1.38	1.47
Leukocytosis	3.60	1.44–9.02	0.01	1.38	1.68
Non-leukocytosis	0.52	0.13–2.04	0.91	1.38	1.68
Neutropenia	0.75	0.11–5.18	1.00	1.38	1.45
Non-neutropenia	1.69	0.66–4.34	0.41	1.38	1.45
Underlying disease, malignancies	1.31	0.48–3.58	0.90	1.38	1.46
Underlying disease, non malignancies	1.65	0.48–5.74	0.48	1.38	1.46
Inappropriate antimicrobial prescription in definitive therapy	9.53	0.60–152.02	0.70	1.38	1.42
Appropriate antimicrobial prescription in definitive therapy	0.74	0.28–1.93	0.77	1.38	1.42
Definitive therapy using carbapenem	3.10	0.21–46.34	0.29	1.38	1.63
Definitive therapy using non-carbapenem	1.25	0.49–3.21	0.45	1.38	1.63
Empiric therapy using cephalosporin	1.10	0.39–3.10	1.00	1.40	1.39
Empiric therapy using non-cephalosporin	2.08	0.51–8.52	0.27	1.40	1.39

RR_strat relative risk from stratification analysis, RR_crude relative risk from total sample, RR_MH relative risk from Mantel Haenzel analysis

ISSN: 1756-0500